leisure time -WSS

leisure time

author：focus 2025-09-30 22:42:20 Page View：96622

Editor’s note: A recording of the event is embedded below.

Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

Let’s dive in and discuss what to watch in the months ahead.

Speakers:

Alex Brill, CEO, Matrix Global Advisors
Chris Brown, managing partner and co-founder, Integrity Rx Partners
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
Thomas Newcomer, head of U.S. market access, Samsung Bioepis (sponsor speaker)

Previous article： Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

explore

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

World's first CRISPR

BillSikes/APLONDON—RegulatorsintheU.K.onThursdayapprovedaCRISPR-basedmedicinetotreatbothsicklecelldi

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Astellas still sees hope in its gene therapy after four deaths

AdobeAgenetherapystudy,haltedwhenfourchildrenwitharareneuromusculardisorderdiedaftertreatment,showed